Celldex Therapeutics Inc (CLDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) has a cash flow conversion efficiency ratio of -0.144x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.59 Million) by net assets ($456.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CLDX market cap overview for the company's overall valuation and market capitalisation.
Celldex Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1986–2025)
This chart illustrates how Celldex Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Celldex Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celldex Therapeutics Inc ranked by their cash flow conversion efficiency. Explore CLDX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OceanaGold Corporation
F:RQQ
|
0.106x |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
0.059x |
|
Hilton Grand Vacations Inc
NYSE:HGV
|
0.095x |
|
Fermi Inc.
NASDAQ:FRMI
|
-0.007x |
|
Corporación Inmobiliaria Vesta S.A.B. de C.V
MX:VESTA
|
0.014x |
|
Aperam SA
MC:APAM
|
0.042x |
|
Organización Soriana S. A. B. de C. V
MX:SORIANAB
|
0.047x |
|
Shanghai Huace Navigation Technology Ltd
SHE:300627
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Celldex Therapeutics Inc (1986–2025)
The table below shows the annual cash flow conversion efficiency of Celldex Therapeutics Inc from 1986 to 2025. View latest Celldex Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $527.16 Million | $-210.94 Million | -0.400x | -89.45% |
| 2024-12-31 | $747.00 Million | $-157.78 Million | -0.211x | +15.51% |
| 2023-12-31 | $429.17 Million | $-107.29 Million | -0.250x | +21.38% |
| 2022-12-31 | $326.20 Million | $-103.73 Million | -0.318x | -119.00% |
| 2021-12-31 | $419.48 Million | $-60.91 Million | -0.145x | +24.76% |
| 2020-12-31 | $209.36 Million | $-40.40 Million | -0.193x | +60.90% |
| 2019-12-31 | $94.03 Million | $-46.41 Million | -0.494x | +18.60% |
| 2018-12-31 | $124.06 Million | $-75.23 Million | -0.606x | -43.44% |
| 2017-12-31 | $236.37 Million | $-99.93 Million | -0.423x | +0.72% |
| 2016-12-31 | $265.43 Million | $-113.04 Million | -0.426x | -24.93% |
| 2015-12-31 | $290.11 Million | $-98.89 Million | -0.341x | +28.94% |
| 2014-12-31 | $211.66 Million | $-101.54 Million | -0.480x | -126.71% |
| 2013-12-31 | $319.80 Million | $-67.67 Million | -0.212x | +59.29% |
| 2012-12-31 | $95.77 Million | $-49.78 Million | -0.520x | -0.18% |
| 2011-12-31 | $68.72 Million | $-35.66 Million | -0.519x | -28.57% |
| 2010-12-31 | $75.25 Million | $-30.37 Million | -0.404x | +0.33% |
| 2009-12-31 | $73.77 Million | $-29.87 Million | -0.405x | -140.17% |
| 2008-12-31 | $18.13 Million | $18.28 Million | 1.008x | -0.54% |
| 2007-12-31 | $-19.04 Million | $-19.30 Million | 1.014x | -91.89% |
| 2006-12-31 | $2.16 Million | $27.00 Million | 12.494x | +4437.96% |
| 2005-12-31 | $20.89 Million | $-6.02 Million | -0.288x | -6.91% |
| 2004-12-31 | $38.41 Million | $-10.35 Million | -0.269x | +35.92% |
| 2003-12-31 | $27.92 Million | $-11.74 Million | -0.420x | +20.89% |
| 2002-12-31 | $31.34 Million | $-16.66 Million | -0.531x | -15.53% |
| 2001-12-31 | $45.27 Million | $-20.83 Million | -0.460x | -459.83% |
| 2000-12-31 | $53.93 Million | $-4.43 Million | -0.082x | +83.24% |
| 1999-12-31 | $17.41 Million | $-8.54 Million | -0.490x | -3.59% |
| 1998-12-31 | $18.80 Million | $-8.90 Million | -0.473x | +61.27% |
| 1997-12-31 | $6.30 Million | $-7.70 Million | -1.222x | -96.56% |
| 1996-12-31 | $15.60 Million | $-9.70 Million | -0.622x | -25.93% |
| 1995-12-31 | $16.00 Million | $-7.90 Million | -0.494x | +4.51% |
| 1994-12-31 | $17.60 Million | $-9.10 Million | -0.517x | -173.56% |
| 1993-12-31 | $29.10 Million | $-5.50 Million | -0.189x | +3.08% |
| 1992-12-31 | $20.00 Million | $-3.90 Million | -0.195x | +32.40% |
| 1991-12-31 | $10.40 Million | $-3.00 Million | -0.288x | 0.00% |
| 1990-12-31 | $10.40 Million | $-3.00 Million | -0.288x | -439.84% |
| 1989-12-31 | $13.10 Million | $-700.00K | -0.053x | +35.88% |
| 1988-12-31 | $8.40 Million | $-700.00K | -0.083x | -107.05% |
| 1986-12-31 | $10.40 Million | $12.30 Million | 1.183x | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more